📰 Regulating Stem Cells News
Page 2 - Regulating Stem Cells News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Regulating Stem Cells. Real-time updates on events, politics, business and more.
January 11, 2022
Calgary, Alberta--(Newsfile Corp. - January 11, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VFO) ("Hemostemix" or the "Company") is pleased to announce it has signed a contract with Dr.
December 9, 2021
Calgary, Alberta--(Newsfile Corp. - December 9, 2021) - Hemostemix Inc. (TSXV: HEM) (OTCQB :HMTXF) (FSE: 2VFO) ("Hemostemix" or the "Company") is pleased to announce the source document verification process
October 28, 2021
Calgary, Alberta--(Newsfile Corp. - October 28, 2021) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VFO) ("Hemostemix" or the "Company") is pleased to announce it is now up-listed to trade on the
October 14, 2021
Calgary, Alberta--(Newsfile Corp. - October 14, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VFO) ("Hemostemix" or the "Company") is pleased to announce the appointment of Dr. Fraser C. Henderson
October 4, 2021
Calgary, Alberta--(Newsfile Corp. - October 4, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") is pleased to announce the second in its series of video interviews with
July 6, 2021
Hemostemix Inc.: Hemostemix Announces Warrant Repricing and Extension Calgary, Alberta--(Newsfile Corp. - July 5, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VFO) ("Hemostemix" or the "Company") is pleased to announce, subject to TSX Venture Exchange Approval, that it has extended for two years and repriced to $0.55 from $1, subject to the accelerator provisions stated below on all repriced warrants, 1,332,500 Warrants expiring July 9, 2021; extended 918,450 Warrants expiring Nove...
May 25, 2021
Hemostemix Inc.: Hemostemix to Present at the Emerging Growth Conference Hemostemix" or the " Company") is pleased to announce that it will present live at the Emerging Growth Conference on May 26, 2021 from 3:30 - 4:00 ET and it invites shareholders, individual and institutional investors, as well as advisors and analysts to attend its real-time, interactive presentation. Attendees are invited to register here to ensure you are able to attend the conference and receive any updates that are rel...
May 11, 2021
Hemostemix Inc.: Hemostemix Announces Closing of Unit Private Placement Hemostemix" or the " Units") announced on April 9, 2021, for gross proceeds of $440,031.90 (the " Offering"). The Offering consisted of the issuance of an aggregate of 1,257,234 Units at a price of $0.35 per Unit. Each Unit consists of one common share in the capital of the Company (" Common Share") and one transferable common share purchase warrant (" Warrant"), with each full Warrant entitling the holder to acquire one Co...
May 7, 2021
Hemostemix Inc.: Hemostemix Announces Warrant Repricing and Extension Hemostemix" or the " Company") is pleased to announce that it has, subject to TSX Venture Exchange Approval, repriced to $0.55 each, and extended the exercise period for two years, the Warrants expiring May 7, 2020 and May 28, 2020, subject to the accelerator provisions, such that the exercise period of Warrants will be reduced to thirty (30) days, if, for any ten consecutive trading days during the unexpired term of the Warr...
May 1, 2021
Calgary, Alberta--(Newsfile Corp. - April 30, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce that, with the last patient follow up